IP Library Granted Patent US 8,202,851
Granted Patent B2
US 8,202,851 · App. 13/301,183 · Granted Jun 19, 2012

Antisense oligonucleotides for treating allergy and neoplastic cell proliferation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,202,851
App. No.
13/301,183
Granted
Jun 19, 2012
Kind
B2
Abstract

Antisense oligonucleotides for treating and/or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors.

Claims (4)

1. A pharmaceutical composition comprising two oligonucleotides consisting of SEQ ID NO. 13 and SEQ ID NO. 14 and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is topical.

3. A method for treating asthma in a subject, comprising the step of administering to the subject an effective amount of the pharmaceutical comprising two oligonucleotides consisting of SEQ ID NO. 13 and SEQ ID NO. 14.

4. The method of claim 3 , wherein the method is for treating asthma.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT APPLICATION NUMBER. PREVIOUSLY RECORDED AT REEL: 038619 FRAME: 0354. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Mar 23, 2017
From: TOPIGEN PHARMACEUTICALS
To: PHARMAXIS LTD
Reel/Frame 042103/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2016
From: TOPIGEN PHARMACEUTICALS, INC.
To: PHARMAXIS LTD
Reel/Frame 038619/0354 →